Related Experiment Video
Updated: Dec 31, 2025
06:55
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
15.0K
Drug utilization in the Maastricht Study: A comparison with nationwide data
Johannes T H Nielen1,2, Johanna H M Driessen1,2,3,4, Pieter C Dagnelie2,5,6
1Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center.
Medicine
|January 3, 2020
Summary
The Maastricht Study
Area of Science:
- Epidemiology
- Pharmacology
- Public Health
Background:
- The Maastricht Study is a prospective, population-based cohort study investigating Type 2 diabetes mellitus (T2DM) etiology in the southern Netherlands.
- Assessing the representativeness of cohort study populations is vital for generalizability.
- Drug utilization serves as a proxy for population health status and healthcare needs.
Purpose of the Study:
- To evaluate the representativeness of the Maastricht Study population.
- To compare drug utilization patterns between Maastricht Study participants and the general Dutch population.
- To determine if Maastricht Study data on drug use is suitable for outcome research.
Main Methods:
- A sampling method was employed to adjust for oversampling of T2DM patients.
- Drug utilization data from the Maastricht Study was compared with national data for the Netherlands.
- A Z-test for independent proportions was used to analyze differences in drug use.
Main Results:
- Overall drug use in the Maastricht Study was largely comparable to national data for the 45-74 age group.
- In the 65-74 age group, total drug use was lower in the study population (833/1000) versus the general population (882/1000).
- Specific differences included lower pulmonary medication use and higher hypnotic/anxiolytic use in the Maastricht Study participants within this age bracket.
Conclusions:
- Drug utilization in the Maastricht Study is broadly representative of the Dutch population aged 45-74.
- The findings support the use of Maastricht Study data for research on drug use outcomes.
- Minor variations in specific drug classes warrant consideration in specific age groups.
More Related Videos
Related Concept Videos
01:16Bioequivalence Data: Statistical Interpretation
162
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
162
01:20Measurement of Bioavailability: Pharmacodynamic Methods
182
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
182
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
239
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
239
01:12Analysis of Population Pharmacokinetic Data
626
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
626
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
115
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
115
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
104
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
104